PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma

Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoman, Wu, Changjing, Chen, Nianci, Gu, Huadi, Yen, Allen, Cao, Liu, Wang, Enhua, Wang, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078108/
https://www.ncbi.nlm.nih.gov/pubmed/26967052
http://dx.doi.org/10.18632/oncotarget.7961
_version_ 1782462314641883136
author Li, Xiaoman
Wu, Changjing
Chen, Nianci
Gu, Huadi
Yen, Allen
Cao, Liu
Wang, Enhua
Wang, Liang
author_facet Li, Xiaoman
Wu, Changjing
Chen, Nianci
Gu, Huadi
Yen, Allen
Cao, Liu
Wang, Enhua
Wang, Liang
author_sort Li, Xiaoman
collection PubMed
description Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation of many downstream signal pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sensitive mTOR-complex (mTOR) pathway. Here we explored the reason why inhibition of the pathway may serve as a compelling therapeutic target for the disease, and provided an update data of EFGR and PI3K/Akt/mTOR inhibitors in clinical trials.
format Online
Article
Text
id pubmed-5078108
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-50781082016-10-28 PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma Li, Xiaoman Wu, Changjing Chen, Nianci Gu, Huadi Yen, Allen Cao, Liu Wang, Enhua Wang, Liang Oncotarget Review Glioblastoma multiform (GBM) is the most common malignant glioma of all the brain tumors and currently effective treatment options are still lacking. GBM is frequently accompanied with overexpression and/or mutation of epidermal growth factor receptor (EGFR), which subsequently leads to activation of many downstream signal pathways such as phosphatidylinositol 3-kinase (PI3K)/Akt/rapamycin-sensitive mTOR-complex (mTOR) pathway. Here we explored the reason why inhibition of the pathway may serve as a compelling therapeutic target for the disease, and provided an update data of EFGR and PI3K/Akt/mTOR inhibitors in clinical trials. Impact Journals LLC 2016-03-07 /pmc/articles/PMC5078108/ /pubmed/26967052 http://dx.doi.org/10.18632/oncotarget.7961 Text en Copyright: © 2016 Li et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Review
Li, Xiaoman
Wu, Changjing
Chen, Nianci
Gu, Huadi
Yen, Allen
Cao, Liu
Wang, Enhua
Wang, Liang
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
title PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
title_full PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
title_fullStr PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
title_full_unstemmed PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
title_short PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
title_sort pi3k/akt/mtor signaling pathway and targeted therapy for glioblastoma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078108/
https://www.ncbi.nlm.nih.gov/pubmed/26967052
http://dx.doi.org/10.18632/oncotarget.7961
work_keys_str_mv AT lixiaoman pi3kaktmtorsignalingpathwayandtargetedtherapyforglioblastoma
AT wuchangjing pi3kaktmtorsignalingpathwayandtargetedtherapyforglioblastoma
AT chennianci pi3kaktmtorsignalingpathwayandtargetedtherapyforglioblastoma
AT guhuadi pi3kaktmtorsignalingpathwayandtargetedtherapyforglioblastoma
AT yenallen pi3kaktmtorsignalingpathwayandtargetedtherapyforglioblastoma
AT caoliu pi3kaktmtorsignalingpathwayandtargetedtherapyforglioblastoma
AT wangenhua pi3kaktmtorsignalingpathwayandtargetedtherapyforglioblastoma
AT wangliang pi3kaktmtorsignalingpathwayandtargetedtherapyforglioblastoma

Ejemplares similares